News & Analysis as of

Food and Drug Administration (FDA) Medical Marijuana Legislative Agendas

Bradley Arant Boult Cummings LLP

Is Psychedelic Therapy Legislation on the Horizon in Mississippi?

Mississippi is no stranger to criticism or being the butt of jokes alleging its inability or refusal to adapt with the times. And, while some of these stereotypes have some support, Mississippi is quietly silencing some if...more

McDermott Will & Schulte

2024 Health Report - Government Actions Affecting Food, Drug and Medical Device Industries

The food, drug and medical device industries comprise some of the most closely regulated sectors in the United States. The US Food & Drug Administration (FDA) actively exercises authority by constantly changing legislation...more

Sheppard Mullin Richter & Hampton LLP

Bridging the Gap: Cannabis Rescheduling to Align Policy with Research

In a much-anticipated move, sources recently reported that the Drug Enforcement Administration (“DEA”) will recommend rescheduling cannabis from a Schedule I substance to a Schedule III substance under the federal Controlled...more

Bradley Arant Boult Cummings LLP

To Reschedule or To Deschedule: That Is the (Marijuana) Question

Now that the dust is starting to settle on the recent news that the U.S. Department of Health and Human Services (HHS) has recommended to the U.S. Drug Enforcement Agency (DEA) that marijuana be moved from Schedule I to...more

Bradley Arant Boult Cummings LLP

The Great Divide: The Feds’ Differing Approach to Psychedelics and Cannabis

Just as we did, the Food and Drug Administration has recognized the growing enthusiasm for exploring opportunities to use psychedelic medications to treat mental health disorders. In June, FDA issued for the first time draft...more

Foley Hoag LLP - Cannabis and the Law

The Cannabis Rescheduling Recommendation: What it Means and What’s Next

In light of the August 30, 2023 historic recommendation from the U.S. Department of Health and Human Services (HHS) to reschedule cannabis to Schedule III, a multidisciplinary group of attorneys from Foley Hoag’s nationwide...more

McDermott Will & Schulte

Doctor-Patient Relationships and Medical Marijuana: Where Are We Now?

McDermott Will & Schulte on

On December 2, 2022, President Joseph Biden signed the Medical Marijuana and Cannabidiol Research Expansion Act (Cannabis Research Act), which provides a mechanism for industry and academia to access and research cannabis,...more

Sheppard Mullin Richter & Hampton LLP

Movement On CMRE Act and MORE Act On Capitol Hill

On Thursday, March 24, 2022, the Senate unanimously passed the CMRE Act (Cannabidiol and Marihuana Research Expansion Act) and House leadership scheduled the MORE Act (Marijuana Opportunity and Expungement Act) for a floor...more

Seyfarth Shaw LLP

The Week in Weed: July 2020 #4

Seyfarth Shaw LLP on

BALLOT INITIATIVES - We’ll start in Arizona, where officials began verifying signatures this week.  Polls show legalization is much more popular now than it was in 2016, when a legalization initiative was defeated.  Not...more

Seyfarth Shaw LLP

The Week in Weed: July 2020 #3

Seyfarth Shaw LLP on

WHERE DO THE CANDIDATES STAND ON MARIJUANA? Vice President Biden and Senator Bernie Sanders formed a “Unity Task Force” in an effort to bring the party together on various issues. One of them is cannabis. The task force...more

Seyfarth Shaw LLP

The Week in Weed: June 2020 #4

Seyfarth Shaw LLP on

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana. We begin with the claim that the Justice Department brought antitrust actions against cannabis companies due to...more

Seyfarth Shaw LLP

The Week in Weed: June 2020 #2

Seyfarth Shaw LLP on

Our big news this week is that the American Bar Association asked the Small Business Administration to make marijuana-related companies eligible for relief funds....more

Seyfarth Shaw LLP

The Week in Weed: March 2020 #2

Seyfarth Shaw LLP on

FEDERAL NEWS - The big news this week was the FDA’s report to Congress on CBD.  The report did not set out a timeline for usage guidelines, citing the need for more data.  Commissioner Stephen Hahn did indicate he thought...more

Seyfarth Shaw LLP

The Week in Weed: February 2020 #2

Seyfarth Shaw LLP on

Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana. It was a busy week for the states, as Virginia moved towards decriminalization.  The state House and Senate passed...more

King & Spalding

Congress Holds Hearing on Current & Future Federal Cannabis Policies

King & Spalding on

On January 15, 2020, the House Energy & Commerce Committee, Subcommittee on Health held a hearing entitled “Cannabis Policies for the New Decade.” Government witnesses testified from: • the Drug Enforcement...more

Bilzin Sumberg

A Budding Opportunity—Why the CBD Industry Requires Regulation

Bilzin Sumberg on

Manufacturers, distributors, and suppliers of CBD products should embrace and participate in reform to address public health concerns, write Bilzin Sumberg attorneys. Consumer groups like the Arthritis Foundation are stepping...more

BCLP

Congress Presses FDA to Act on CBD Regulations

BCLP on

Following statements by the U.S. Food and Drug Administration that cannabidoil (CBD) in food and beverage products remains illegal, and amid the patchwork of state laws and enforcement actions, a group of U.S. lawmakers, led...more

Lathrop GPM

America's Growing Embrace of Cannabis

Lathrop GPM on

The laws and regulations of the U.S. and each individual state are evolving at a significant pace concerning one genus of flowering plants, and mostly with a tender embrace. Despite being criminalized for the greater part...more

18 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide